We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00578435
Recruitment Status : Completed
First Posted : December 21, 2007
Last Update Posted : September 12, 2008
Sponsor:
Information provided by:
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.

Condition or disease Intervention/treatment Phase
Genetic Disorders Sickle Cell Anemia Procedure: Busulfan, Cyclophosphamide, BMD Phase 2

Detailed Description:

The trial proposed is a single armed phase II treatment protocol designed to examine the engraftment,toxicity and graft-versus-host disease following a novel cytoreductive regimen including cyclophosphamide and Busulfan for the treatment of patients with Severe Sickle Cell Anemia,Thalassemia, and Diamond Blackfan Anemia using stem cell transplants derived from HLA-genotypically identical siblings.

Patients will be conditioned for transplantation with cyclophosphamide (50 mg/kg/day x 4 days), and busulfan [(if < 4 years of age 1 mg/kg 4 times per day x 4 days), (if > 4 years of age 0.8 mg/kg 4 times per day x 4 days)]. Patients will receive Methotrexate & Cyclosporin-A for prophylaxis against GvHD and GCSF to promote engraftment.

The preferred source of stem cells from related HLA-matched related donors will be unmodified bone marrow stem cells.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
Study Start Date : January 1994
Primary Completion Date : August 2008
Study Completion Date : August 2008



Intervention Details:
    Procedure: Busulfan, Cyclophosphamide, BMD
    Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0


Primary Outcome Measures :
  1. Define the role of bone marrow transplantation for the treatment of sickle cell disease and the reversibility of sickle cell vasculopathy and organ damage, good risk thalassemia major and Diamond-Blackfan Anemia. [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with severe HOMOZYGOUS SICKLE CELL ANEMIA or SICKLE/BETA THALASSEMIA
  • Neurologic event (stroke or hemorrhage).
  • Abnormal cerebral MRI scan and cerebral arteriogram or MRI angiographic study (MRA) and impaired neuropsychologic testing.
  • Recurrent acute chest syndrome (> 2 episodes)
  • Stage I-II sickle chronic lung disease
  • Sickle cell nephropathy (moderate or severe proteinuria or GFR 30-50% of predicted for age.
  • Major visual impairment in at least one eye with bilateral proliferative retinopathy.
  • Osteonecrosis of multiple bones
  • Chronic debilitating pain secondary to vasoocclusive crisis (>= 3 episodes per year for >= 3 years) Recurrent priapism
  • Allo-immunization with the development of antibodies following chronic transfusion therapy
  • Patients with HOMOZYGOUS SICKLE CELL ANEMIA or SICKLE/BETA THALASSEMIA with the following criteria will be considered for accrual on this protocol
  • Patients < 2 years with high WBC counts and/or >1 episode of dactylitis and/or a Hgb < 7 g/dl
  • History of death from sickle cell disease in sibship of patient
  • Patients with BETA-THALASSEMIA MAJOR with Lucarelli class 1 or 2 risk status i.e with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor chelation therapy
  • Patients with DIAMOND-BLACKFAN ANEMIA who have failed conventional therapy.
  • Patients must have an HLA-compatible related donor. The donor must be healthy and able to undergo general anesthesia. Donors with heterozygous sickle cell anemia (hemoglobin AS) or with heterozygous thalassemia are acceptable donors.
  • At the time of referral for transplantation, patients must be in good clinical condition without any evidence of infections and a Karnofsky or Lansky pediatric performance scale > 70%
  • Each patient and donor must be willing to participate as a research subject and must sign an informed consent form after having been advised as to the nature and risk of the study prior to entering the protocol. Parents or legal guardians of patients who are minor will sign the consent form after being advised of the nature and risks of the study

Exclusion Criteria:

  • Patients whose life expectancy is less than 8 weeks. Patients with a Karnofsky or Lansky performance score of < 70%
  • Patients with severe major organ dysfunction:
  • Patients with severe renal impairment. This will be determined by a creatinine clearance < 70 ml/min/1.73 m2 (or serum creatinine > 1.5 x Normal) or by a glomerular filtration rate < 30% of predicted normal for age
  • Inadequate cardiac function as determined by fractional shortening < 28% on echocardiogram, and/or ejection fraction of < 50% on echocardiogram or RNCA.
  • Patients with FS of 23-28% who show an increase in FS in response to stress on the supine bicycle ergometer are eligible
  • Major liver dysfunction: SGOT > 3 x upper limit of normal. Hyperbilirubinemia will not be used as an exclusion criteria because of the hemolytic component of the bilirubin. Patients with active hepatitis or severe liver fibrosis will also be excluded
  • Severe residual functional neurologic impairment
  • Stage III-IV sickle chronic lung disease
  • Pregnant or lactating women are excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00578435


Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Investigators
Principal Investigator: Farid Boulad, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Responsible Party: Fourid Boulad, Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00578435     History of Changes
Other Study ID Numbers: 94-005
First Posted: December 21, 2007    Key Record Dates
Last Update Posted: September 12, 2008
Last Verified: September 2008

Keywords provided by Memorial Sloan Kettering Cancer Center:
ERYTHROPOIESIS
Genetic Disorders
Sickle Cell Anemia
Thalassemia
Diamond Blackfan Anemia

Additional relevant MeSH terms:
Disease
Anemia
Anemia, Sickle Cell
Genetic Diseases, Inborn
Pathologic Processes
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Cyclophosphamide
Busulfan
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists